To minimise the risk of toxicity if accidentally ingested by a child, most medicinal cannabis products need to be packaged using child-resistant closures. The exceptions are medicinal products in the form of plant material and those products described in section 6(2) of TGO 93.
Domestic manufacturers of medicinal cannabis products must have a TGA manufacturing licence, demonstrating compliance with Australian Good Manufacturing Principles (GMP). Section 13 sets out equivalent GMP requirements for medicinal cannabis products manufactured overseas.
The 2021 Advertising Code took effect on 1 January 2022 and will be subject to a 6-month transition period until 30 June 2022 where both the 2018 and 2021 Advertising Codes will apply.